

CY 2022 Real World Testing Report for VieCure

Executive Summary

This is the test report for CY 2022 real world testing for our VieCure certified EHR solution. This is the companion document to our CY 2022 real world test plan that described our approach for conducting real world testing in CY 2022 and the testing measures we employed.

Our findings show that EHR is working in our production as it was certified. For each our CY 2022 Real World Testing Measures, we have recorded our results and findings. We did not discover any non-conformities or errors from our testing.

Our signed attestation of compliance with the real world testing requirements is on the following page.



Developer Attestation

This Real World Testing report is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

Authorized Representative Signature: *Heath McMillion*

DATE 1/30/2023



Executive Summary	1
Developer Attestation	2
General Information	4
Timeline and Milestones for Real World Testing CY 2022.....	5
Standards Version Advancement Process (SVAP) Updates	6
RWT Measure #1. Transitions of Care	7
RWT Measure #2. Clinical Information Reconciliation and Incorporation.....	8
RWT Measure #3. NewRx Prescriptions	9
RWT Measure #4. Clinical Quality Measures	10
RWT Measure #5. Number of Patients Given Access to Portal.....	11
RWT Measure #6. Syndromic Surveillance Registries.....	12
RWT Measure #7. Electronic Case Registries.....	13
RWT Measure #8. 3 rd Party API Application Access.....	14



General Information

Plan Report ID Number: VieCure-RWT-2022

Developer Name: **VieCure, Inc**

Product Name(s): VieCure

Version Numbers(s): 3.2

Certified Health IT Criteria: 315(b)(1)-(3), (b)(6), (c)(1), (e)(1), (f)(2), (f)(5), (g)(7)-(9), (h)(1)

Product List (CHPL) ID(s) and Link(s):

- **15.04.04.3066.VieC.03.01.1.210128**
- **<https://chpl.healthit.gov/#/listing/10541>**

Developer Real World Testing Page URL: <https://www.viecure.com/certifications-1>

Timeline and Milestones for Real World Testing CY 2022

- Milestone 1Q-2022: Begin communication with clients to ask for their support and participation in real world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2022.
 - STATUS: Delayed until 4Q because of work on Cures certification.
Completed in 4Q.
- Milestone 2Q-3Q 2022. During the 2nd and 3rd quarter of CY 2022, the real world testing with clients will be scheduled and performed. It is expected that a preparatory call will be done with clients to prepare them for testing activities. Results will be documented in the test results section of the test methods and ultimately used to build the test report. If any non-compliances are observed, we will notify the ONC-ACB of the findings and make the necessary changes required.
 - STATUS: Delayed until 4Q because of work on Cures certification.
Completed in 4Q.
- Milestone 4Q-2022. During the last quarter of the year, the CY 2023 real world test plan will be completed according to ONC and ONC-ACB requirements and expectations. Test plan will be prepared for submission before the end of the year.
 - STATUS: MET
- Milestone 1Q-2023. Submit RWT Test Report to ONC-ACB.
 - STATUS: MET



Standards Version Advancement Process (SVAP) Updates

For CY 2022 RWT testing, we did not do any SVAP updates.

Standard (and version)	N/A
Updated certification criteria and associated product	N/A
CHPL Product Number	N/A
Conformance measure	N/A



RWT Measure #1. Transitions of Care

Associated Criteria: 315(b)(1), (h)(1)

Measurement Description

This measure is tracking and counting the number of messages with CCDAs attached successfully sent.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of messages with CCDAs attached successfully sent

Total: 831 for all clinics during dates of 4Q-2022

Analysis and Key Findings

Generating and sharing of C-CDAs is something our provider community does fairly regularly, and our results indicate our design is meeting their needs. Results also show the integration with our relied upon software HISP, EMRDirect, is working properly in a production setting.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.



RWT Measure #2. Clinical Information Reconciliation and Incorporation

Associated Criteria: 315(b)(2)

Measurement Description

This measure is tracking and counting the number of times reconciliation of medications, allergies and problems is performed.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of reconciliation of medications, allergies and problems from a received C-CDA

Total: 0 for all clinics during dates of 4Q-2022

Analysis and Key Findings

Our clinicians are typically not receiving C-CDAs from other providers, but additional internal testing and audit results do not indicate any errors or failures with the functionality.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.



RWT Measure #3. NewRx Prescriptions

Associated Criteria: 315(b)(3)

Measurement Description

This measure is tracking and counting how many NewRx electronic prescriptions were created and successfully sent from the EHR Module to a pharmacy destination over the course of a given interval. The interval for this measure will be three (3) months

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: Number successfully sent from the EHR Module to a pharmacy destination.

Total: 7,285 for all clinics during dates of 4Q-2022

Analysis and Key Findings

Electronic prescribing is a popular feature with our client base, and our results support its wide spread use.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.



RWT Measure #4. Clinical Quality Measures

Associated Criteria: 315(c)(1)

Measurement Description

This measure is tracking and counting the use of electronic clinical quality measure functionality.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: calculation of patients or episodes of care which meet the numerator criteria of the quality measures certified in the EHR as displayed in our system's CQM dashboard

Total: 0 for all sites during 2022

Analysis and Key Findings

Our clients were not using our CQM capabilities for the CMS MIPS program so they were not generating any eQMs during this test period. We do expect that to change in coming years, and we will be monitoring this metric going forward.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.



RWT Measure #5. Number of Patients Given Access to Portal Associated Criteria: 315(e)(1)

Measurement Description

This measure is tracking and counting how many patients are given login access to their patient portal account.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of patients given login access to their patient portal account

Total: 0 for all clinics during 4Q-2022

Analysis and Key Findings

Our clients choose not to enable their patient portal in CY 2022 which prevented collection of any results for this metric. They have indicated they will enable it and so we expect to have results in future real world test reports. Our additional internal testing and audit results do not indicate any errors or failures with the functionality.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.



RWT Measure #6. Syndromic Surveillance Registries

Associated Criteria: 315(f)(2)

Measurement Description

This measure is tracking and counting the number of organizations with an active syndromic surveillance registry interface.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of syndromic surveillance registries engaged

Total: 0 for all clinics during 2022

Analysis and Key Findings

The results align with the feedback we received from our clinician community that they do not use this functionality regularly in their practices. Syndromic surveillance is not something done by cancer care centers.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.



RWT Measure #7. Electronic Case Registries

Associated Criteria: 315(f)(5)

Measurement Description

This measure is tracking and counting the number of organizations with an active syndromic surveillance registry interface.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of electronic case registries engaged

Total: 0 for all clinics during 2022

Analysis and Key Findings

The results align with the feedback we received from our clinician community that they do not use this functionality regularly in their practices. Electronic case reporting is not something done by cancer care centers.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.



RWT Measure #8. 3rd Party API Application Access

Associated Criteria: 315(g)(7)-(9)

Measurement Description

This measure is tracking and counting the number of organizations with an active syndromic surveillance registry interface.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of different systems or applications are connecting to the EHR via the API

Total: 0 for all clinics during 2022

Analysis and Key Findings

We did not have any requests to use our certified API functionality. With the adoption of the new Cures updated FHIR v4 315(g)(10) criteria, this number may change in CY 2023. Our additional internal testing and audit results do not indicate any errors or failures with the functionality.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.